Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan; Department of Pathology and Clinical Laboratory, JR Tokyo General Hospital, 2-1-3 Yoyogi, Shibuya-ku, Tokyo, 151-8528, Japan.
Hum Pathol. 2024 Sep;151:105630. doi: 10.1016/j.humpath.2024.105630. Epub 2024 Jul 26.
This study aimed to analyze the heterogeneity or change in cell of origin (COO) in diffuse large B-cell lymphoma (DLBCLs) using the Hans algorithm including 156 patients with multiple DLBCL specimens. COO was detected via immunohistochemical staining for CD10, BCL6, and MUM1. The COO of the main tumor at initial diagnosis was germinal center B-cell (GCB) and non-GCB type in 50 (32%) and 106 (68%) patients, respectively. It did not change in 126 patients (81%). However, it changed in 30 patients (19%), from GCB to non-GCB in 12 patients and vice versa in 18 patients. The COO was heterogeneous or changed in 14% of simultaneous samples at other sites during the initial diagnosis, in 7% of primary refractory sites, and in 20% of samples obtained in the relapse phase other than the primary site. Changes in CD10, BCL6, and MUM1 expression were observed in 15%, 23%, and 24% samples, respectively. A low incidence of change in COO was observed in DLBCL with CD10/BCL6/MUM1 (4%), CD10/BCL6/MUM1 (3%), and CD10/BCL6/MUM1 (0%) patterns, whereas DLBCL with other patterns showed COO changes at rates of 20-37%. In conclusion, COO was heterogeneous or changed in 19% of DLBCL cases. The COO should be re-examined in other biopsy samples to determine the optimal treatment.
本研究旨在使用包括 156 例多发性 DLBCL 标本的 Hans 算法分析弥漫性大 B 细胞淋巴瘤 (DLBCL) 中细胞起源 (COO) 的异质性或变化。通过免疫组织化学染色检测 CD10、BCL6 和 MUM1 来检测 COO。在初始诊断时,主要肿瘤的 COO 为生发中心 B 细胞 (GCB) 和非 GCB 型,分别为 50 例 (32%) 和 106 例 (68%)。在 126 例患者 (81%) 中未发生变化。然而,在 30 例患者 (19%) 中发生了变化,12 例从 GCB 转变为非 GCB,18 例反之亦然。在初始诊断时其他部位同时采集的样本中,COO 存在异质性或变化的占 14%,原发性难治性部位占 7%,原发性部位以外的复发阶段样本占 20%。CD10、BCL6 和 MUM1 表达的变化分别在 15%、23%和 24%的样本中观察到。在 CD10/BCL6/MUM1(4%)、CD10/BCL6/MUM1(3%)和 CD10/BCL6/MUM1(0%)模式的 DLBCL 中观察到 COO 变化的发生率较低,而其他模式的 DLBCL 则表现出 20-37%的 COO 变化率。总之,19%的 DLBCL 病例存在 COO 异质性或变化。在其他活检样本中应重新检查 COO,以确定最佳治疗方案。